Tuesday, January 12, 2021 10:39:22 AM
January 12, 2021 07:52 ET | Source: Ocugen
MALVERN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced it has determined to withdraw from stockholder consideration Item 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on October 30, 2020, with respect to an increase in the number of shares of common stock authorized for issuance under the Company’s Sixth Amended and Restated Certificate of Incorporation.
Recent OCGN News
- Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 06/21/2024 11:00:00 AM
- Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 06/20/2024 10:30:31 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/18/2024 08:29:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:31:02 PM
- Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy • GlobeNewswire Inc. • 05/31/2024 12:36:49 PM
- Ocugen to Present at BIO International Convention 2024 • GlobeNewswire Inc. • 05/29/2024 11:15:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:05:59 PM
- Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 • GlobeNewswire Inc. • 05/28/2024 11:02:39 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 • GlobeNewswire Inc. • 05/20/2024 11:00:52 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/17/2024 08:30:54 PM
- Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 05/15/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 07:54:50 PM
- Ocugen Provides Business Update with First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 12:00:25 PM
- US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report • IH Market News • 05/14/2024 11:18:01 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:02 AM
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 05/10/2024 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:14:11 PM
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock • GlobeNewswire Inc. • 05/10/2024 08:05:06 PM
- Ocugen to Present at May 2024 Investor Conferences • GlobeNewswire Inc. • 05/10/2024 11:45:07 AM
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/03/2024 11:30:05 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress • GlobeNewswire Inc. • 05/02/2024 11:15:46 AM
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 • GlobeNewswire Inc. • 04/29/2024 10:45:00 AM
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 01:05:24 PM
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 10:30:40 AM
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy • GlobeNewswire Inc. • 04/19/2024 11:13:05 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM